Thabut Gabriel, Mal Herve
Service de pneumologie et transplantation pulmonaire, Hôpital Bichat, Paris, France.
INSERM U1152, Université Paris Diderot, Paris, France.
J Thorac Dis. 2017 Aug;9(8):2684-2691. doi: 10.21037/jtd.2017.07.85.
With more than 50,000 procedures having been performed worldwide, lung transplantation (LT) has become the standard of care for patients with end-stage chronic respiratory failure. LT leads to dramatic improvements in both pulmonary function and health related quality of life. Survival after LTs has steadily improved, but still lags far behind that observed after other solid organ transplantations, as evidenced by a median survival rate that currently stands at 5.8 years. Because of these disappointing results, the ability of LT to expand survival has been questioned. However, the most recent studies, based on sophisticated statistical modeling suggest that LT confers a survival benefit to the vast majority of lung transplant recipients. Chronic lung allograft dysfunction (CLAD) that develops in about 50% of recipients 5 years after LT is a major impediment to lung transplant survival. A better understanding of the mechanisms underlying CLAD could allow for better post-transplant survival.
全球范围内已进行了超过50000例手术,肺移植(LT)已成为终末期慢性呼吸衰竭患者的标准治疗方法。肺移植可显著改善肺功能和与健康相关的生活质量。肺移植后的生存率稳步提高,但仍远远落后于其他实体器官移植后的生存率,目前的中位生存率为5.8年就证明了这一点。由于这些令人失望的结果,肺移植延长生存期的能力受到了质疑。然而,基于复杂统计模型的最新研究表明,肺移植给绝大多数肺移植受者带来了生存益处。约50%的受者在肺移植后5年出现的慢性肺移植功能障碍(CLAD)是肺移植生存的主要障碍。更好地了解CLAD的潜在机制有助于提高移植后的生存率。